• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

提出一个对接受肺转移瘤切除术的患者总生存有意义的替代终点:局部治疗失败时间。

Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure.

机构信息

Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Department of Mathematical Health Science, Osaka University Graduate School of Medicine, Suita, Japan.

出版信息

World J Surg. 2019 Oct;43(10):2640-2646. doi: 10.1007/s00268-019-05071-2.

DOI:10.1007/s00268-019-05071-2
PMID:31243525
Abstract

BACKGROUND

A recent study demonstrated remarkable discrepancy between the relapse-free survival (RFS) and overall survival (OS) after pulmonary metastasectomy (PM) in the current era. As the RFS may not be a suitable parameter after PM, a more suitable parameter is needed for PM as a surrogate marker for OS.

METHODS

A total of 134 consecutive patients who underwent PM were retrospectively analyzed. In the present study, we introduced a new endpoint, time to local treatment failure (TLTF). This endpoint was defined as the time interval between the first PM and the first untreatable recurrence by local treatment with curative intent or death due to any cause. We analyzed the correlation between the RFS and OS and between the TLTF and OS to validate whether or not the TLTF is a better parameter than the RFS after PM.

RESULTS

Thus far, 78 patients have experienced relapse. Of these, 37 patients (47%) underwent local therapy with curative intent, 29 of whom are alive without local treatment failure. The 5-year OS, RFS and TLTF were 70.9%, 36.5%, and 57.6%, respectively. The concordance proportions for the RFS and OS and for the TLTF and OS were 0.634 and 0.851 for all patients, respectively. The Spearman's rank correlation coefficient for the RFS and OS was 0.639, while that for the TLTF and OS was 0.875.

CONCLUSIONS

The TLTF may be a good surrogate parameter for the OS after PM in the current era.

摘要

背景

最近的一项研究表明,在当前时代,肺转移瘤切除术(PM)后的无复发生存率(RFS)和总生存率(OS)之间存在显著差异。由于 RFS 可能不是 PM 后的合适参数,因此需要一个更合适的参数作为 PM 的替代标志物来预测 OS。

方法

回顾性分析了 134 例连续接受 PM 的患者。在本研究中,我们引入了一个新的终点,即局部治疗失败时间(TLTF)。该终点定义为首次 PM 与首次因局部治疗(有治愈意图)而无法治疗的复发或任何原因导致的死亡之间的时间间隔。我们分析了 RFS 与 OS 之间以及 TLTF 与 OS 之间的相关性,以验证 TLTF 是否是 PM 后比 RFS 更好的参数。

结果

迄今为止,78 例患者出现复发。其中,37 例(47%)接受了有治愈意图的局部治疗,其中 29 例患者在没有局部治疗失败的情况下存活。5 年 OS、RFS 和 TLTF 分别为 70.9%、36.5%和 57.6%。所有患者的 RFS 和 OS 以及 TLTF 和 OS 的一致性比例分别为 0.634 和 0.851。RFS 和 OS 的 Spearman 秩相关系数为 0.639,而 TLTF 和 OS 的 Spearman 秩相关系数为 0.875。

结论

TLTF 可能是当前时代 PM 后 OS 的一个良好替代参数。

相似文献

1
Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure.提出一个对接受肺转移瘤切除术的患者总生存有意义的替代终点:局部治疗失败时间。
World J Surg. 2019 Oct;43(10):2640-2646. doi: 10.1007/s00268-019-05071-2.
2
Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure.可切除结直肠癌肝转移患者无复发生存期与总生存期的差异:手术失败时间的潜在替代终点
Ann Surg Oncol. 2014 Jun;21(6):1817-24. doi: 10.1245/s10434-014-3504-1. Epub 2014 Feb 6.
3
Prognostic factors after pulmonary metastasectomy of colorectal cancers: influence of liver metastasis.结直肠癌肺转移切除术后的预后因素:肝转移的影响
World J Surg Oncol. 2016 Jul 29;14(1):201. doi: 10.1186/s12957-016-0940-3.
4
Prognosis of patients with recurrence after pulmonary metastasectomy for colorectal cancer.结直肠癌肺转移切除术后复发患者的预后。
Gen Thorac Cardiovasc Surg. 2020 Oct;68(10):1172-1178. doi: 10.1007/s11748-020-01368-5. Epub 2020 Apr 22.
5
Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma.肉瘤肺转移瘤切除术患者生存改善的结局及临床预测因素
J Surg Oncol. 2015 Jul;112(1):103-6. doi: 10.1002/jso.23961. Epub 2015 Jul 14.
6
Pulmonary metastasectomy in colorectal cancer patients with previously resected liver metastasis: pooled analysis.既往有肝转移切除史的结直肠癌患者的肺转移瘤切除术:汇总分析
Ann Surg Oncol. 2015;22(6):1844-50. doi: 10.1245/s10434-014-4173-9. Epub 2014 Oct 18.
7
Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators?头颈部癌肺转移瘤切除术的生存和预后因素:哪些是具有临床意义的预后指标?
Eur J Cardiothorac Surg. 2019 May 1;55(5):942-947. doi: 10.1093/ejcts/ezy384.
8
Do Repeated Operations for Recurrent Colorectal Lung Metastases Result in Improved Survival?复发性结直肠肺转移行多次手术是否能改善生存?
Ann Thorac Surg. 2018 Aug;106(2):421-427. doi: 10.1016/j.athoracsur.2018.02.065. Epub 2018 Mar 30.
9
Long-Term Outcomes of Pulmonary Metastasectomy for Uterine Malignancies: A Multi-institutional Study in the Current Era.在当前时代,对子宫恶性肿瘤行肺转移切除术的长期预后:一项多机构研究。
Ann Surg Oncol. 2020 Oct;27(10):3821-3828. doi: 10.1245/s10434-020-08426-5. Epub 2020 Apr 9.
10
Survival Outcome and Prognostic Factors After Pulmonary Metastasectomy in Sarcoma Patients: A 18-Year Experience at a Single High-volume Referral Center.肉瘤患者肺转移瘤切除术的生存结局和预后因素:单一大容量转诊中心 18 年的经验。
Am J Clin Oncol. 2019 Jan;42(1):6-11. doi: 10.1097/COC.0000000000000476.

引用本文的文献

1
Results of redo pulmonary metastasectomy.再次肺转移瘤切除术的结果。
J Thorac Dis. 2021 Apr;13(4):2669-2685. doi: 10.21037/jtd-19-4064.

本文引用的文献

1
Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.软组织肉瘤治疗的 II 期临床试验中的研究性治疗。
Expert Opin Investig Drugs. 2019 Jan;28(1):39-50. doi: 10.1080/13543784.2019.1555236. Epub 2018 Dec 5.
2
The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.手术在转移性膀胱癌中的作用:系统评价。
Eur Urol. 2018 Apr;73(4):543-557. doi: 10.1016/j.eururo.2017.09.030. Epub 2017 Nov 7.
3
Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?软组织肉瘤是否适合重复肺转移瘤切除术?
Ann Thorac Surg. 2017 Dec;104(6):1837-1845. doi: 10.1016/j.athoracsur.2017.07.024. Epub 2017 Nov 2.
4
Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases.肺癌寡转移的手术或立体定向放疗的长期疗效。
J Thorac Oncol. 2017 Sep;12(9):1442-1445. doi: 10.1016/j.jtho.2017.05.015. Epub 2017 May 30.
5
Role of pulmonary metastasectomy in colorectal cancer in the era of modern multidisciplinary therapy.现代多学科治疗时代肺转移瘤切除术在结直肠癌中的作用
Surg Today. 2017 Sep;47(9):1111-1118. doi: 10.1007/s00595-017-1478-x. Epub 2017 Feb 15.
6
Surgery for malignant pulmonary nodules in patients with a history of oesophageal cancer.有食管癌病史患者的恶性肺结节手术治疗
Interact Cardiovasc Thorac Surg. 2017 Mar 1;24(3):418-424. doi: 10.1093/icvts/ivw358.
7
Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study.姑息治疗预后研究(PiPS)预测模型的开发,以改善晚期癌症的预后:前瞻性队列研究。
BMJ Support Palliat Care. 2015 Dec;5(4):390-8. doi: 10.1136/bmjspcare-2012-d4020rep.
8
Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection.肺转移瘤切除术:根据手术切除类型的结果及问题
Gen Thorac Cardiovasc Surg. 2015 Jun;63(6):320-30. doi: 10.1007/s11748-015-0544-9. Epub 2015 Apr 3.
9
Survival is higher after repeat lung metastasectomy than after a first metastasectomy: Too good to be true?重复肺转移瘤切除术的生存率高于首次转移瘤切除术:这好得难以置信?
J Thorac Cardiovasc Surg. 2015 May;149(5):1249-52. doi: 10.1016/j.jtcvs.2015.01.067. Epub 2015 Feb 11.
10
Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer.射频消融治疗结直肠癌肺转移
World J Gastroenterol. 2014 Jan 28;20(4):988-96. doi: 10.3748/wjg.v20.i4.988.